BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is a San Rafael, California-based biotechnology company founded in 1997 that focuses on medicines for genetically defined rare diseases. Its business is built around eight commercial therapies, including VOXZOGO, VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA, KUVAN and ROCTAVIAN, plus a pipeline of clinical and preclinical programs. The company develops and commercializes category-defining treatments for serious and life-threatening conditions where patient populations are small but medically urgent. BioMarin sells directly in the U.S. and major international markets, while also using distributors and partners in selected countries. Its model combines internal R&D, targeted acquisitions and partnerships to expand its rare-disease portfolio over time.

15,2 %

77,7 %

10,8 %

+12,9 %

5.21

3.50

— BioMarin Pharmaceutical Inc
%
Skeletal conditions29% Therapies for genetically defined skeletal disorders, centered on VOXZOGO.
Enzyme therapies63% Enzyme replacement and related therapies for ultra-rare metabolic and lysosomal diseases.
Gene therapy1% One-time or durable genetic medicines such as ROCTAVIAN for hemophilia A.
Legacy and other products7% Older products including KUVAN and smaller revenue streams from other commercialized assets.

BioMarin sells primarily to specialty pharmacies, hospitals, government purchasers and authorized distributors that...

  • U.S. specialty pharmaciesprimary

    Buy VOXZOGO, PALYNZIQ and other products for dispensing to patients, because access and reimbursement are managed through specialty channels.

  • Hospitals and treatment centersprimary

    Purchase infused or administered therapies for rare-disease patients, especially in the U.S. and Europe.

  • Government purchasers and public health systemsprimary

    Place periodic large orders in certain countries, which drives international volume but also creates timing volatility.

  • Authorized distributorssecondary

    Buy products for selected non-U.S. markets and handle local regulatory and commercial execution.

  • Sanofiprimary

    Sole customer for ALDURAZYME, purchasing and commercializing the product globally.

BioMarin is headquartered in the United States and sells directly through commercial teams in the U.S...

  • •United States is the core commercial market and headquarters location
  • •Europe is a major direct-sales region for VOXZOGO and ROCTAVIAN
  • •South America contributes through direct sales and distributor channels
  • •Middle East and Latin America can drive large government orders
  • •Selected markets are served by local distributors rather than BioMarin directly
  • •International sales timing can be uneven because of public-sector ordering
  • •Global operations create foreign exchange and regulatory exposure

BioMarin is focused on expanding its rare-disease franchise while selectively advancing or discontinuing R&D programs...

01
Expand VOXZOGO globallyshort-term

VOXZOGO is a major growth driver and broadening patient initiation supports recurring rare-disease revenue.

02
Strengthen the enzyme therapies portfoliomedium-term

Enzyme replacement therapies remain the core cash-generating franchise and provide diversification across ultra-rare diseases.

03
Advance pipeline and portfolio disciplinemedium-term

Rare-disease biotech depends on a steady flow of differentiated assets, but capital must be focused on programs with the best commercial odds.

04
Optimize commercialization and cost structureshort-term

A focused sales organization and cost transformation can improve efficiency while supporting launches and international expansion.

BioMarin faces the typical risks of a rare-disease biotech company: dependence on a small number of products,...

high

Dependence on a limited number of commercial products

A large share of revenue comes from a small set of rare-disease therapies, so any slowdown in one product can materially affect results.

Scope
VOXZOGO, enzyme therapies, KUVAN
Materiality
high
high

Generic competition and loss of exclusivity

KUVAN has already been pressured by generic competition, showing the vulnerability of mature products after exclusivity ends.

Scope
KUVAN
Materiality
high
high

Manufacturing and supply chain disruption

Biologic and enzyme therapies require reliable third-party logistics, raw materials and finished-product supply to meet demand and support trials.

Scope
Global manufacturing and distribution
Materiality
high
high

Regulatory and clinical development risk

Pipeline value depends on successful trials and approvals, and setbacks can eliminate expected future revenue.

Scope
BMN 333, BMN 401 and other pipeline programs
Materiality
high
high

Counterparty dependence on Sanofi

ALDURAZYME is sold globally by Sanofi, so termination or disruption of that agreement would impair commercialization.

Scope
ALDURAZYME
Materiality
high
medium

Large periodic government orders create revenue timing volatility

Certain countries place bulk orders inconsistently, which can shift revenue between quarters and complicate forecasting.

Scope
Latin America, Middle East, other public-sector markets
Materiality
high
Revenue recognition and variable consideration
Net revenue and quarterly comparability
ALDURAZYME sell-through accounting
Revenue timing and estimate true-ups
Government order timing and seasonality
Quarterly revenue volatility
Acquisition and asset accounting
Balance sheet and expense recognition
Impairment and program discontinuation judgments
R&D expense and asset values

Camp4 Therapeutics Corp

CAMP · Pharmaceutical Preparations

ALNYLAM PHARMACEUTICALS, INC.

ALNY · Pharmaceutical Preparations

BIOGEN INC.

BIIB · Biological Products, (No Diagnostic Substances)

Benitec Biopharma Inc.

BNTC · Pharmaceutical Preparations

Ultragenyx Pharmaceutical Inc.

RARE · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

: 11/08/2026